Get startedLog in
    Picture of SynAct Pharma AB logo

    SYNACT — SynAct Pharma AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    All News

    Brief: Synact Pharma Completes Part 1 Of Phase II Trial With AP1189 For Rheumatoid Arthritis

    Picture of SynAct Pharma AB logoSynAct Pharma AB
    12/10/2020 06:54
    Oct 12 (Reuters) - SynAct Pharma AB  SYNACT.TE :
    * COMPLETES PART 1 OF PHASE II CLINICAL TRIAL WITH AP1189
FOR
RHEUMATOID ARTHRITIS
    * DATA REVIEW INDICATES THAT SUBSTANCE IS SAFE AND TOLERATED
WELL

Source text for Eikon:  ID:nWkr92zF9Y 
Further company coverage:  SYNACT.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))

    Recent news on SynAct Pharma AB

    See all news